Tectonic Therapeutic Inc
For the period ended Jun 30, 2024. Filed Aug 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 14, 2024
TECX$21.89+6.1%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Cash Flows
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
| June 30, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows from operating activities: | ||
| Net loss | $(27,892) | $(24,900) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization expense | 713 | 734 |
| Stock-based compensation expense | 724 | 552 |
| Non-cash lease expense | 595 | 549 |
| Change in fair value of SAFE liabilities | 3,610 | — |
| Change in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | (252) | (479) |
| Other non-current assets | 422 | (14) |
| Accounts payable | (70) | 1,706 |
| Accrued expenses and other current liabilities | 153 | 1,645 |
| Operating lease liabilities | (658) | (336) |
| Net cash used in operating activities | (22,655) | (20,543) |
| Cash flows from investing activities: | ||
| Purchase of property, equipment and improvements | — | (222) |
| Net cash used in investing activities | — | (222) |
| Cash flows from financing activities: | ||
| Proceeds from the Subscription Agreement, net of offering costs of $2,000 | 94,600 | — |
| Cash acquired in connection with the Merger | 85,230 | — |
| Payment for Merger transaction costs | (1,168) | — |
| Proceeds from exercise of common stock options | 648 | 1 |
| Repayment of finance lease obligations | (240) | (270) |
| Net cash provided by (used in) financing activities | 179,070 | (269) |
| Effect of exchange rate changes on cash and cash equivalents | (60) | — |
| Net increase (decrease) in cash and cash equivalents and restricted cash | 156,355 | (21,034) |
| Cash and cash equivalents and restricted cash as of beginning of period | 29,356 | 36,553 |
| Cash and cash equivalents and restricted cash as of end of period | $185,711 | $15,519 |
| Components of cash, cash equivalents and restricted cash: | ||
| Cash and cash equivalents | $185,124 | $14,932 |
| Restricted cash | 587 | 587 |
| Total cash, cash equivalents and restricted cash | $185,711 | $15,519 |
| Supplemental disclosure of non-cash financing activities: | ||
| Merger transaction costs included in accounts payable and accrued expenses and other current liabilities | $8,769 | $— |
| Conversion of SAFEs to Common Stock | $34,125 | $— |
| Conversion of Convertible Preferred Stock to Common Stock | $80,627 | $— |
| Supplemental disclosure of cash flow information: | ||
| Cash paid for interest | $59 | $82 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.